EU/3/09/613

Table of contents

About

Please note that this product (marketed as Vantobra) was withdrawn from the Community Register of designated orphan medicinal products in June 2014 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 27 February 2009, orphan designation (EU/3/09/613) was granted by the European Commission to PARI Pharma GmbH , Germany, for tobramycin (inhalation use) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis.

Key facts

Active substance
Tobramycin (inhalation use)
Disease / condition
Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis
Date of decision
28/02/2009
Outcome
Positive
Orphan decision number
EU/3/09/613

Sponsor's contact details

PARI Pharma GmbH
Moosstrasse 3
82319 Starnberg
Germany
Tel. +49 89 74284651
Fax +49 89 74284630
E-mail: info@paripharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating